

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

SENATE BILL 180

**53RD LEGISLATURE - STATE OF NEW MEXICO - FIRST SESSION, 2017**

INTRODUCED BY

Gerald Ortiz y Pino

AN ACT

RELATING TO HEALTH; AMENDING THE NEW MEXICO DRUG, DEVICE AND  
COSMETIC ACT TO PROVIDE FOR REGULATION OF BIOSIMILAR PRODUCTS.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF NEW MEXICO:

SECTION 1. Section 26-1-2 NMSA 1978 (being Laws 1967,  
Chapter 23, Section 2, as amended) is amended to read:

"26-1-2. DEFINITIONS.--As used in the New Mexico Drug,  
Device and Cosmetic Act:

A. "board" means the board of pharmacy or its duly  
authorized agent;

B. "person" includes an individual, partnership,  
corporation, association, institution or establishment;

C. "biological product" means a virus, therapeutic  
serum, toxin, antitoxin, protein or analogous product  
applicable to the prevention, treatment or cure of diseases or

underscoring material = new  
[bracketed material] = delete

underscoring material = new  
[bracketed material] = delete

1 injuries of humans and domestic animals, and, as used within  
2 the meaning of this definition:

3 (1) a "virus" is interpreted to be a product  
4 containing the minute living cause of an infectious disease and  
5 includes filterable viruses, bacteria, rickettsia, fungi and  
6 protozoa;

7 (2) a "therapeutic serum" is a product  
8 obtained from blood by removing the clot or clot components and  
9 the blood cells;

10 (3) a "toxin" is a product containing a  
11 soluble substance poisonous to laboratory animals or humans in  
12 doses of one milliliter or less of the product and, following  
13 the injection of nonfatal doses into an animal, having the  
14 property of or causing to be produced therein another soluble  
15 substance that specifically neutralizes the poisonous substance  
16 and that is demonstrable in the serum of the animal thus  
17 immunized; ~~and~~

18 (4) an "antitoxin" is a product containing the  
19 soluble substance in serum or other body fluid of an immunized  
20 animal that specifically neutralizes the toxin against which  
21 the animal is immune; and

22 (5) a "protein" excludes any chemically  
23 synthesized polypeptide;

24 D. "controlled substance" means a drug, substance  
25 or immediate precursor enumerated in Schedules I through V of

.204843.3MS

underscored material = new  
~~[bracketed material] = delete~~

1 the Controlled Substances Act;

2 E. "drug" means articles:

3 (1) recognized in an official compendium;

4 (2) intended for use in the diagnosis, cure,  
5 mitigation, treatment or prevention of disease in humans or  
6 other animals and includes the domestic animal biological  
7 products regulated under the federal Virus-Serum-Toxin Act, 37  
8 Stat 832-833, 21 U.S.C. 151-158, and the biological products  
9 applicable to humans regulated under Federal 58 Stat 690, as  
10 amended, 42 U.S.C. 216, Section 351, 58 Stat 702, as amended,  
11 and 42 U.S.C. 262;

12 (3) other than food, that affect the structure  
13 or any function of the human body or the bodies of other  
14 animals; and

15 (4) intended for use as a component of  
16 Paragraph (1), (2) or (3) of this subsection, but "drug" does  
17 not include devices or their component parts or accessories;

18 F. "dangerous drug" means a drug, other than a  
19 controlled substance enumerated in Schedule I of the Controlled  
20 Substances Act, that because of a potentiality for harmful  
21 effect or the method of its use or the collateral measures  
22 necessary to its use is not safe except under the supervision  
23 of a practitioner licensed by law to direct the use of such  
24 drug and hence for which adequate directions for use cannot be  
25 prepared. "Adequate directions for use" means directions under

.204843.3MS

underscored material = new  
~~[bracketed material] = delete~~

1 which the layperson can use a drug or device safely and for the  
2 purposes for which it is intended. A drug shall be dispensed  
3 only upon the prescription or drug order of a practitioner  
4 licensed by law to administer or prescribe the drug if it:

5 (1) is a habit-forming drug and contains any  
6 quantity of a narcotic or hypnotic substance or a chemical  
7 derivative of such substance that has been found under the  
8 federal act and the board to be habit forming;

9 (2) because of its toxicity or other potential  
10 for harmful effect or the method of its use or the collateral  
11 measures necessary to its use is not safe for use except under  
12 the supervision of a practitioner licensed by law to administer  
13 or prescribe the drug;

14 (3) is limited by an approved application by  
15 Section 505 of the federal act to the use under the  
16 professional supervision of a practitioner licensed by law to  
17 administer or prescribe the drug;

18 (4) bears the legend: "Caution: federal law  
19 prohibits dispensing without prescription.";

20 (5) bears the legend: "Caution: federal law  
21 restricts this drug to use by or on the order of a licensed  
22 veterinarian."; or

23 (6) bears the legend "RX only";

24 G. "counterfeit drug" means a drug that is  
25 deliberately and fraudulently mislabeled with respect to its

.204843.3MS

underscoring material = new  
~~[bracketed material] = delete~~

1 identity, ingredients or sources. Types of such pharmaceutical  
2 counterfeits may include:

3 (1) "identical copies", which are counterfeits  
4 made with the same ingredients, formulas and packaging as the  
5 originals but not made by the original manufacturer;

6 (2) "look-alikes", which are products that  
7 feature high-quality packaging and convincing appearances but  
8 contain little or no active ingredients and may contain harmful  
9 substances;

10 (3) "rejects", which are drugs that have been  
11 rejected by the manufacturer for not meeting quality standards;  
12 and

13 (4) "relabels", which are drugs that have  
14 passed their expiration dates or have been distributed by  
15 unauthorized foreign sources and may include placebos created  
16 for late-phase clinical trials;

17 H. "device", except when used in Subsection [P] Q  
18 of this section and in Subsection G of Section 26-1-3,  
19 Subsection L and Paragraph (4) of Subsection A of Section  
20 26-1-11 and Subsection C of Section 26-1-24 NMSA 1978, means an  
21 instrument, apparatus, implement, machine, contrivance,  
22 implant, in vitro reagent or other similar or related article,  
23 including any component, part or accessory, that is:

24 (1) recognized in an official compendium;

25 (2) intended for use in the diagnosis of

.204843.3MS

underscoring material = new  
~~[bracketed material] = delete~~

1 disease or other conditions or in the cure, mitigation,  
2 treatment or prevention of disease in humans or other animals;  
3 or

4 (3) intended to affect the structure or a  
5 function of the human body or the bodies of other animals and  
6 that does not achieve any of its principal intended purposes  
7 through chemical action within or on the human body or the  
8 bodies of other animals and that is not dependent on being  
9 metabolized for achievement of any of its principal intended  
10 purposes;

11 I. "prescription" means an order given individually  
12 for the person for whom prescribed, either directly from a  
13 licensed practitioner or the practitioner's agent to the  
14 pharmacist, including by means of electronic transmission, or  
15 indirectly by means of a written order signed by the  
16 prescriber, and bearing the name and address of the prescriber,  
17 the prescriber's license classification, the name and address  
18 of the patient, the name and quantity of the drug prescribed,  
19 directions for use and the date of issue;

20 J. "practitioner" means a certified advanced  
21 practice chiropractic physician, physician, doctor of oriental  
22 medicine, dentist, veterinarian, euthanasia technician,  
23 certified nurse practitioner, clinical nurse specialist,  
24 pharmacist, pharmacist clinician, certified nurse-midwife,  
25 physician assistant, prescribing psychologist, dental

.204843.3MS

underscored material = new  
[bracketed material] = delete

1 hygienist, optometrist or other person licensed or certified to  
2 prescribe and administer drugs that are subject to the New  
3 Mexico Drug, Device and Cosmetic Act;

4 K. "cosmetic" means:

5 (1) articles intended to be rubbed, poured,  
6 sprinkled or sprayed on, introduced into or otherwise applied  
7 to the human body or any part thereof for cleansing,  
8 beautifying, promoting attractiveness or altering the  
9 appearance; and

10 (2) articles intended for use as a component  
11 of any articles enumerated in Paragraph (1) of this subsection,  
12 except that the term shall not include soap;

13 L. "interchangeable biological product" means a  
14 biological product that:

15 (1) the federal food and drug administration  
16 has licensed and determined to meet the federal standards for  
17 "interchangeable" or "interchangeability"; or

18 (2) the federal food and drug administration  
19 has determined to be a therapeutic equivalent as set forth in  
20 the latest edition of or supplement to the federal food and  
21 drug administration's approved drug products with therapeutic  
22 equivalence evaluations, also known as the "orange book";

23 [~~E.~~] M. "official compendium" means the official  
24 United States pharmacopoeia national formulary or the official  
25 homeopathic pharmacopoeia of the United States or any

.204843.3MS

underscoring material = new  
~~[bracketed material] = delete~~

1 supplement to either of them;

2           ~~[M-]~~ N. "label" means a display of written, printed  
3 or graphic matter upon the immediate container of an article.  
4 A requirement made by or under the authority of the New Mexico  
5 Drug, Device and Cosmetic Act that any word, statement or other  
6 information appear on the label shall not be considered to be  
7 complied with unless the word, statement or other information  
8 also appears on the outside container or wrapper, if any, of  
9 the retail package of the article or is easily legible through  
10 the outside container or wrapper;

11           ~~[N-]~~ O. "immediate container" does not include  
12 package liners;

13           ~~[O-]~~ P. "labeling" means all labels and other  
14 written, printed or graphic matter:

15                   (1) on an article or its containers or  
16 wrappers; or

17                   (2) accompanying an article;

18           ~~[P-]~~ Q. "misbranded" means a label to an article  
19 that is misleading. In determining whether the label is  
20 misleading, there shall be taken into account, among other  
21 things, not only representations made or suggested by  
22 statement, word, design, device or any combination of the  
23 foregoing, but also the extent to which the label fails to  
24 reveal facts material in the light of such representations or  
25 material with respect to consequences that may result from the

.204843.3MS



underscoring material = new  
~~[bracketed material] = delete~~

1 use of the article to which the label relates under the  
2 conditions of use prescribed in the label or under such  
3 conditions of use as are customary or usual;

4 ~~[Q-]~~ R. "advertisement" means all representations  
5 disseminated in any manner or by any means, other than by  
6 labeling, for the purpose of inducing, or that are likely to  
7 induce, directly or indirectly, the purchase of drugs, devices  
8 or cosmetics;

9 ~~[R-]~~ S. "antiseptic", when used in the labeling or  
10 advertisement of an antiseptic, shall be considered to be a  
11 representation that it is a germicide, except in the case of a  
12 drug purporting to be or represented as an antiseptic for  
13 inhibitory use as a wet dressing, ointment, dusting powder or  
14 such other use as involves prolonged contact with the body;

15 ~~[S-]~~ T. "new drug" means a drug:

16 (1) the composition of which is such that the  
17 drug is not generally recognized, among experts qualified by  
18 scientific training and experience to evaluate the safety and  
19 efficacy of drugs, as safe and effective for use under the  
20 conditions prescribed, recommended or suggested in the labeling  
21 thereof; or

22 (2) the composition of which is such that the  
23 drug, as a result of investigation to determine its safety and  
24 efficacy for use under such conditions, has become so  
25 recognized, but that has not, otherwise than in such

underscored material = new  
[bracketed material] = delete

1 investigations, been used to a material extent or for a  
2 material time under such conditions;

3 ~~[F.]~~ U. "contaminated with filth" applies to a  
4 drug, device or cosmetic not securely protected from dirt, dust  
5 and, as far as may be necessary by all reasonable means, from  
6 all foreign or injurious contaminations, or a drug, device or  
7 cosmetic found to contain dirt, dust, foreign or injurious  
8 contamination or infestation;

9 ~~[H.]~~ V. "selling of drugs, devices or cosmetics"  
10 shall be considered to include the manufacture, production,  
11 processing, packing, exposure, offer, possession and holding of  
12 any such article for sale and the sale and the supplying or  
13 applying of any such article in the conduct of a drug or  
14 cosmetic establishment;

15 ~~[V.]~~ W. "color additive" means a material that:

16 (1) is a dye, pigment or other substance made  
17 by a process of synthesis or similar artifice or extracted,  
18 isolated or otherwise derived, with or without intermediate or  
19 final change of identity, from a vegetable, mineral, animal or  
20 other source; or

21 (2) when added or applied to a drug or  
22 cosmetic or to the human body or a part thereof, is capable,  
23 alone or through reaction with other substances, of imparting  
24 color thereto; except that such term does not include any  
25 material that has been or hereafter is exempted under the

.204843.3MS

underscored material = new  
[bracketed material] = delete

1 federal act;

2 [W.] X. "federal act" means the Federal Food, Drug,  
3 and Cosmetic Act;

4 [~~X.~~] Y. "restricted device" means a device for  
5 which the sale, distribution or use is lawful only upon the  
6 written or oral authorization of a practitioner licensed by law  
7 to administer, prescribe or use the device and for which the  
8 federal food and drug administration requires special training  
9 or skills of the practitioner to use or prescribe. This  
10 definition does not include custom devices defined in the  
11 federal act and exempt from performance standards or premarket  
12 approval requirements under Section 520(b) of the federal act;

13 [~~Y.~~] Z. "prescription device" means a device that,  
14 because of its potential for harm, the method of its use or the  
15 collateral measures necessary to its use, is not safe except  
16 under the supervision of a practitioner licensed in this state  
17 to direct the use of such device and for which "adequate  
18 directions for use" cannot be prepared, but that bears the  
19 label: "Caution: federal law restricts this device to sale by  
20 or on the order of a \_\_\_\_\_", the blank to be filled with  
21 the word "physician", "physician assistant", "certified  
22 advanced practice chiropractic physician", "doctor of oriental  
23 medicine", "dentist", "veterinarian", "euthanasia technician",  
24 "certified nurse practitioner", "clinical nurse specialist",  
25 "pharmacist", "pharmacist clinician", "certified nurse-

.204843.3MS

underscored material = new  
[bracketed material] = delete

1 midwife", [~~or~~] "dental hygienist" or "optometrist" or with the  
2 descriptive designation of any other practitioner licensed in  
3 this state to use or order the use of the device;

4 [~~Z.~~] AA. "valid practitioner-patient relationship"  
5 means a professional relationship, as defined by the  
6 practitioner's licensing board, between the practitioner and  
7 the patient;

8 [~~AA.~~] BB. "pedigree" means the recorded history of  
9 a drug; and

10 [~~BB.~~] CC. "drug order" means an order either  
11 directly from a licensed practitioner or the practitioner's  
12 agent to the pharmacist, including by means of electronic  
13 transmission or indirectly by means of a written order signed  
14 by the licensed practitioner or the practitioner's agent, and  
15 bearing the name and address of the practitioner and the  
16 practitioner's license classification and the name and quantity  
17 of the drug or device ordered for use at an inpatient or  
18 outpatient facility."

19 **SECTION 2.** Section 26-3-3 NMSA 1978 (being Laws 1976,  
20 Chapter 60, Section 4, as amended) is amended to read:

21 "26-3-3. DRUG AND BIOLOGICAL PRODUCT SELECTION  
22 PERMITTED--CONDITIONS--EXCEPTION FOR PROHIBITION--LABELING.--

23 A. Upon receipt of a prescription written by a  
24 licensed practitioner who may prescribe drugs or biological  
25 products for a drug or biological product for which one or more

.204843.3MS

underscored material = new  
[bracketed material] = delete

1 multiple-source drugs or interchangeable biological products  
2 are recognized, listed as final determinations and published in  
3 the federal register by the federal department of health and  
4 human services, a pharmacist may dispense any one of the drugs  
5 or interchangeable biological products that satisfies the final  
6 determinations so recognized and listed by the federal  
7 department of health and human services and is sold at a lower  
8 cost than the drug or biological product listed in the  
9 prescription.

10 B. Upon receipt of a prescription written by a  
11 licensed practitioner for a drug or biological product that  
12 appears on the federal food and drug administration's approved  
13 prescription drug products with therapeutic equivalence  
14 evaluation list as supplemented, or for a biological product  
15 that is listed as interchangeable on the list of the federal  
16 food and drug administration's lists of licensed biological  
17 products with reference product exclusivity and biosimilar or  
18 interchangeable evaluations, as supplemented, a pharmacist may  
19 dispense any of the listed therapeutically equivalent drugs or  
20 interchangeable biological products that ~~[appears on that list~~  
21 ~~and which]~~ is lower in cost than the prescribed drug ~~[listed in~~  
22 ~~the prescription]~~ or biological product.

23 C. Drug and biological product selection shall be  
24 permitted only under circumstances and conditions set forth in  
25 Subsections A and B of this section unless:

.204843.3MS

underscored material = new  
[bracketed material] = delete

1                   (1) the licensed practitioner prescribing  
2 prohibits drug product or biological product selection. A  
3 licensed practitioner shall prohibit drug or biological product  
4 selection by [~~writing with his hand~~] handwriting the words "no  
5 substitution" or the diminution "no sub" on the face of a  
6 prescription; or

7                   (2) in the case of a biological product, the  
8 person, or representative of the person, for whom the  
9 biological product is prescribed requests the prescribed  
10 biological product.

11                   D. If drug or biological product selection occurs  
12 as permitted in Subsections A and B of this section, the  
13 pharmacist shall indicate on the label of the dispensed  
14 container the brand of drug or the specific biological product  
15 prescribed and the name of the drug or interchangeable  
16 biological product dispensed.

17                   E. A pharmacist who selects an interchangeable  
18 biological product shall, prior to dispensing an  
19 interchangeable biological product, inform the patient or the  
20 patient's representative that:

21                               (1) an interchangeable biological product will  
22 be substituted for the biological product prescribed; and

23                               (2) the patient, or the patient's  
24 representative, has the right to refuse the substitution and  
25 request that the prescribed biological product be dispensed.

underscored material = new  
[bracketed material] = delete

1           ~~[E.]~~ F. A pharmacist may not select a  
2           therapeutically equivalent drug or interchangeable biological  
3           product unless ~~[he]~~ the pharmacist passes on to the patient all  
4           savings between the net cost of the product prescribed and the  
5           product dispensed.

6                   ~~[F. For purposes of this section, "multiple-source~~  
7                   ~~drug" means a drug marketed or sold by two or more~~  
8                   ~~manufacturers, formulators or labelers.]~~

9                   G. Within five business days following the  
10                  dispensing of a biological product, the dispensing pharmacist  
11                  or the pharmacist's designee shall make an entry of the  
12                  specific product provided to the patient, including the name of  
13                  the product and the manufacturer. The communication shall be  
14                  conveyed by making an entry that is electronically accessible  
15                  to the prescriber through:

- 16                           (1) an interoperable electronic medical
- 17                           records system;
- 18                           (2) an electronic prescribing technology;
- 19                           (3) a pharmacy benefit management system; or
- 20                           (4) a pharmacy record.

21                  H. Entry into an electronic records system pursuant  
22                  to Subsection G of this section is presumed to provide notice  
23                  to the prescriber. Otherwise, the pharmacist shall communicate  
24                  the biological product dispensed to the prescriber using  
25                  facsimile, telephone, electronic transmission or other

underscoring material = new  
~~[bracketed material] = delete~~

1 prevailing means; provided that communication shall not be  
2 required when:

3 (1) there is no interchangeable biological  
4 product that has been approved by the federal food and drug  
5 administration for the product prescribed; or

6 (2) a refill prescription is not changed from  
7 the product dispensed on the prior filling of the prescription.

8 I. The board shall maintain a link on its website  
9 to the current list of all biological products that the federal  
10 food and drug administration has determined to be  
11 interchangeable biological products.

12 ~~[G.]~~ J. For purposes of this section:

13 (1) "multiple-source drug" means a drug  
14 marketed or sold by two or more manufacturers, formulators or  
15 labelers; and

16 (2) "therapeutically equivalent" means drug  
17 products ~~[which]~~ that have the same amount of the active drug  
18 in the same dosage form ~~[which]~~ that when administered can be  
19 expected to provide the same therapeutic effect."